Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment

• <i>Background:</i> In Prader-Willi syndrome (PWS) obesity and partial growth hormone (GH) deficiency are frequently observed. The risks of cardiovascular diseases and early death are increased. We examined inflammatory markers in adult PWS, before and during 12 months of GH treatment. <i>Method:</i> Twelve PWS adults, median age 23.5 years (17–37) and median BMI 33.8 kg/m² (21.2–50.4), participated. Serum interleukin-6, tumour necrosis factor α, high sensitive protein C-reactive protein (HCRP), cholesterol, triglycerides, leptin, adiponectin, glucose, insulin, insulin-like growth factor I and body composition were measured at baseline and after 6 and 12 months of GH treatment. <i>Results:</i> Median and range at baseline for interleukin-6 was 9.87 ng/l (1.76–10.72), for tumour necrosis factor α 2.39 ng/l (1.00–3.26) and for HCRP 7.64 mg/l (0.41–41.1) (normal values < 5 ng/l, < 8 ng/l and<5 mg/l, respectively). At baseline correlations between inflammatory markers and age, anthropometry, body composition and the metabolic parameters were non-significant; only positive associations were found between tumour necrosis factor α and body weight (r = 0.617, p = 0.033) and between HCRP and BMI (r = 0.594, p = 0.041). GH treatment non-significantly decreased the levels of the inflammatory markers. <i>Conclusion:</i> In this pilot study, levels of interleukin-6 and HCRP were increased, and GH intervention did not significantly reduce the levels. Chronic inflammation might contribute to the increased cardiovascular morbidity and mortality in PWS.

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)